Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer's Disease in Primary Care

Sponsor
Imperial College London
Study ID
NCT07401849
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Alzheimer Disease
  • Biomarker in Early Diagnosis
  • Biomarkers / Blood
  • Mild Cognitive Impairment (MCI)

Eligibility Criteria

Sex
ALL
Age
55 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Alzheimer's disease is a degenerative condition affecting the brain and is the most common form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people. The progression of the disease varies between individuals and the early stages may be characterised by only minimal changes in memory and thinking. These changes could remain undetected as the symptoms may be mistakenly regarded as normal age-related forgetfulness. However, dementia is not part of the normal ageing process. The underlying biological disease process of Alzheimer's is now known to start at least 20 years prior to patients showing any symptoms. A protein called amyloid starts to deposit in the brain and forms clumps referred to as 'plaques'. Another protein called tau collects inside brain cells and forms structures called 'tangles'. These biological changes can disrupt the normal functioning of brain cells and ultimately destroy them, leading to a reduction in brain volume and ability. The aim of the BEAD-PC study is to assess whether a specific blood test in primary care can help diagnose Alzheimer's disease at an early stage.

Key Dates

First listed
Feb 11, 2026
Start date
Feb 28, 2026
Status verified
Feb 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Presence of Alzheimer-specific blood biomarkers [ Time Frame: Day 1 (study entry) ]

Central Contacts

Find similar trials

Nationwide
Alzheimer's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials

Related Studies